High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment

Sanchez-Magraner, L; Miles, J; Baker, CL; Applebee, CJ; Lee, DJ; Elsheikh, S; Lashin, S; Withers, K; Watts, AG; Parry, R; Edmead, C; Lopez, JI; Mehta, R; Italiano, A; Ward, SG; Parker, PJ; Larijani, B

Parker, PJ (corresponding author), Francis Crick Inst, Prot Phosphorylat Lab, 1Midland Rd, London NW1 1AT, England.; Larijani, B (corresponding author), Univ Bath, Ctr Therapeut Innovat, Bath BA2 7AY, Avon, England.

CANCER RESEARCH, 2020; 80 (19): 4244

Abstract

Many cancers are termed immunoevasive due to expression of immunomodulatory ligands. Programmed death ligand-1 (PD-L1) and cluster of differentiation ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索